Aug, 2013

Coland Holdings LimitedTWSE 4144

2

Disclaimer

• The presentation and the relevant information mentioned in this material, including operating performance, financial performance and the business outlook, have been compiled from both internal and external resources.

• These forward looking statements involve known and unknown risks, uncertainties and other factors, including price variation, competition, global economy, exchange rate movement and market demand, which may cause actual results to differ materially from those implied by such forward-looking statements.

• This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

• The forward looking statements expressed in this material reflect the Company’s current view about the future as of today. The Company is not responsible for any updates if there are any changes in the future.

3

Contents

Value Creation – Coland Style

Executive Summary

Outstanding Performance

Strategy for Future Growth

Appendix

Financial Performance

• We are the only Taiwan-listed, China-focused company specializing in the commercialization of healthcare products.

• We excel in product sourcing, registration, branding and marketing.

• Our superior performance is led by an industry-leading MNC-experienced, senior management team.

• Our unique Taiwan market insights and expertise enable us to source best-in-class healthcare products.

• We are strongly committed to providing superior returns to our shareholders.

4

Value Creation – Coland Style

5

Expand and Diversify Products

Build a Superior Pipeline

Leverage Strengths of Strategic Partners

Expand Network Coverage

Strong Product Sourcing and

Branding Capability

Extensive Sales Network

Experienced and Stable International Management Team

Superior Performance

Relative to Peers

Outstanding Performance Strategy for Future Growth

Executive Summary

6

Value Creation – Coland Style

Executive Summary

Outstanding Performance

Strategy for Future Growth

Appendix

Financial Performance

1. Strong Product Sourcing and Branding

7

Product Development

Manufacturing Sales & Marketing Distribution

Colandcollaborates with leading healthcare companies to develop promising products.

Dedicated in Product Sourcing

Colandcooperates with high quality GMP manufacturers.

Partner with high quality manufacturers

Our sales and marketing professionals promote products to China’s top hospitals.

Build and Develop a Professional Promotion Team

Work with nationwide top tier distributors.

Work with National Distributors to build National Network

Coland’s Strategic Focus

Milestones Accomplished since IPO in 2011

New Products Anti-HBV drug Lamivudine Yin Ding from Anhui Beike, COPD drug Bi Duo Yi and Rhinitis drug Yi Qing from Zhejiang Xianju

More Hospitals Increased coverage to over 2000 hospitals across China

More MNC products

In-licensed antibiotic injection Augmentin from GSK，Olbetam(Acipimox) and Detrusitol from Pfizer

M&A Purchased and obtained 51% equity of Heilongjiang TongzePharmaceutical company in July 2012 Strategic investments in Taiwan/PRC companies

New Medical Device Partners

Agreed to purchase in HC-BIOS-Dental Implant, Suzhou Micro Clear-Ophthalmoscope, Rendu Biotechnology-IVD reagents

8

Current Main Products

99

Therapeutic Area Year Product Generic name Indications Supplier

Hepatitis 2005 Dai Ding Adefovir Anti-HBV

Tianjin Institute of Pharmaceutical

Research

2012 Yin Ding Lamivudine Anti-HBV/HIVAnhui Biochem

United Pharmaceutical Co

Respiratory2011 Bi Duo Yi Tiotropium

Bromide COPD Zhejiang’s XianjuPharmaceutical

2013 Yi QingMometasone

Furoate Aqueous Nasal Spray

Rhinitis Zhejiang’s XianjuPharmaceutical

Immuno-suppressant 2005 Shun You Mycophenolate

MofetilOrgan

TransplantZhejiang JianfengPharmaceutical

Antibiotics 2012 Augmentin AmoxicillinandClavulanate

Bacteria Infection GSK

Cardiovascular 2013 Lezhiping Olbetam Treatment of Hyperlipidemia Pfizer

Urology 2013 Detrol TolterodineTartrate

Treatment of OAB Pfizer

Medical Device 2010 Sofamor Spinal Implants Spine Surgery Medtronic

10

8600+ Medical doctors2000+ Hospitals400+ Sales representatives200+ Distributors10 Sales offices1 Joint Venture (Heilongjiang Tongze)

Heilongjiang

Jilin

Liaoning

Beijing

Tianjin

Inner Mongolia

Hebei

Shandong

Jiangsu

Shanghai

Zhejiang

Fujian

Taiwan

Hainan

Guangdong

MacaoHong Kong

Guangxi

JiangxiHunan

Xinjiang

Tibet

Qinghai

Gansu

Sichuan

Yunnan

ChongqingHubei

Anhui

Henan

Shanxi

Shaanxi

Ningxia

Guizhou

• Success of blockbuster drug Dai Ding led to completion ofa national sales network

• Existing hospital network covers 50% of Tier-III, 30% of Tier-II hospitals

• M&A to accelerate pace of expansion

2. Extensive Sales Network

William Keller

Chairman

Key BOD Members captained the industry-leading Roche China Team in the late 1990s

Leo Lee

Co-Founderand Director

Xiaoping Ye

Co-Founderand Director

• As Head of S&M at Roche China, led company to win No.1 market share in prescription drugs in China

• Strengths in sales and management, especially the ability to retain talent

• Over 20-years career in China pharma industry, having worked at Johnson & Johnson, Schering-Plough, and Roche

• Ex-Medical Director at Roche China is key figure in contributing to Coland’ssuperior drug sourcing and pipeline capability

• Specializes in clinical trials for CFDA approval. Chaired 2 Pegasys Global Phase III studies for HBV at Roche

• Keen eye for CFDA / Market potential in drugs

• Key to identifying strategic partners for Coland

• Over 30-years management experience with Roche Pharma Group

• Held senior positions in Roche South America and Roche Asia

• GM of Roche China from 1995 until his retirement in 2002

• In 1999, was granted Honorary Citizenship of Shanghai and permanent resident permit in China for his outstanding contributions

11

3. Experienced and Stable Int’l Mgmt Team

Experienced and Stable Int’l Mgmt Team

Johua TsaoCFO20-yrs experience Int’l FMCG companies in Greater ChinaP&G, Dairy Farm( N. Asia Finance Head)

Tong HuNational Sales & Marketing Director15-yrs experienceShanghai SA, Roche, Novartis

David ChengCIO20-yrs experienceBoston Bioventure, YFY Bioventure Fund

Feng WangNational Sales DirectorOver 15-yrs experienceTong Sheng, Roche

Wenge Han Medical Registration DirectorOver 20-yrs experienceSanofi, Eddingpharm HK, Servier

Laura Guo, MDExternal Affairs Director20-yrs experienceSchering-Plough, Roche, NT Pharma

Jin-Fang LouProduct Development DirectorOver 20-yrs experienceNT Pharma, Hangzhou Saili, Hainan Puli

Sophie Jiang, MDMedical Device DirectorOver 20-yrs experienceAstra, Roche, Pharmacia & Upjohn

Leo LeeCEOOver 20-yrs experienceJ&J, Schering-Plough, and Roche

12

13

4. Coland vs. GC and International PeersColand has superior ROE and the highest yield, yet trades at a significant discount to peers

*Greater China peers: China Chemical & Pharma, CMS, Lee’s Pharm, Medigen, NT Pharma, Sihuan Pharm, Simcere Pharm, Sino Biopharm, Sinphar Pharm, TTY Biopharm, and United Lab.** International peers: Johnson & Johnson, Roche, and Pfizer.

-

5.0

10.0

15.0

20.0

25.0

30.0

Coland Greater China peer median*

International peer median**

(%) ROE

20112012

-1.0 2.0 3.0 4.0 5.0 6.0 7.0

Coland Greater China peer median*

International peer median**

(%) Dividend Yield

20112012

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

Coland Greater China peer median* International peer median**

(x) P/E20112012

14

Coland vs. GC and International PeersColand has superior FCF generation capability and high cash reserves

-60

-40

-20

0

20

40

60

80

Coland CMS Sino Biopharm

United Lab Lee's Pharma

Simcere Roche Pfizer

Net Cash/Total Assets2011

2012

％

-25

-20

-15

-10

-5

0

5

10

15

20

Coland CMS Sino Biopharm

United Lab Lee's Pharma

Simcere Roche Pfizer

FCF Yield 20112012

％

15

Value Creation – Coland Style

Executive Summary

Appendix

Financial Performance

Outstanding Performance

Strategy for Future Growth

Core Strategy

Build the best GC healthcare commercialization platform

Extensive sales network with national scale

Proven track record: Top-3 share in Adefovir sales

Source high-quality Rx drugs and Medical Devices

Prefer First-to-Market generics

Multiple sources: China, Taiwan, and International

Diversify product portfolio

Rich product offering: Rx drugs, Medical devices, IVD reagents

Product in-licensing, strategic investments, JV, and M&A

16

1. Expand and Diversify Products

Newlaunches At least one new product launch each year

Differentiation Sources: Class 1 New Drugs, FTM generics, MNC drugs

New therapeutic areas: Oncology, Respiratory, Cardiovascular

Medical device offerings Orthopedic (trauma & joint), dental, ophthalmology, IVD reagents

Operational excellence

Solidify leadership in hepatitis and respiratory drugs

Constant focus on high quality and best value proposition

17

Major New Products in 2013

Yi Qing(Mometasone furoate)

Aqueous nasal spray(Schering-Plough’s Nasonex®)

In-Licensed from producer Zhejiang Xianju and already included in the NRDL, Yi Qing targets the over RMB 500m-a-year nasal spray market in China.

Lezhiping is used for lowering high levels of cholesterol and triglycerides in the blood. It is a top-2 brand in China currently. Market size is RMB 80m in annual sales in China, according to IMS.

Detrol SR has been the world’s No.1 Rx drug for OAB since its 1998 debut. China’s RMB45m OAB market is projected to grow at a 25% CAGR between 2011-2015. Pfizer’s Detrol market share is 10% vs. 40% for Nanjing Meirui’s Tolterodine.

Lezhiping(acipimox capsules)

Cholesterol Reduction(Pfizer’s Olbetam®)

Detrol(Tolterodine L-Tartrate Sustained Release Capsules)

Overactive Bladder (OAB)(Pfizer’s Detrusitol SR®)

18

Dynamic Growth of Non-Daiding Sales

2.2%8.5%

17.7%

25.9%

31.0%

• Non-Daiding products grew from 0% in 2007 to 39.3% in 1H13• Non-Daiding sales grew at a 83.3% CAGR in 2008-2012*

19

*64.4% excluding contribution from Heilongjiang Tongze Pharmaceutical.

0.0%2.3% 2.2%

8.5%

17.7%

25.9%

39.3%

0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

35.0%

40.0%

45.0%

2007 2008 2009 2010 2011 2012 1H13

Non-Daiding sales

20

2. Building a Superior Pipeline

First-to-Market Generic

International Patented Products

Timing and branding are critical factors for fast market penetration

Products with international IP enjoy much longer life cycle

CFDA Class 1 New Drug Enjoy preferential pricing, tender-bidding rights, and insurance reimbursement

Pharma Product Pipeline

21

Indications Medicine Name 2014 2015 2016 2017 2018 2019 2020

Hepatitis

Entecavir dispersible tablets

Recom. HSA-Interferon α2b fusion

Tenofovir

Respiratory

Compound ipratropium bromide

Ciclesonide aerosol

Beclomethasone dipropionate Aerosol

Oncology

Irinotecan Injection

Temozolomide capsule

Vorinostat

Capecitabine

Imatinib

Bortezomib

G.I. Alvimopan

C.V. Metoprolol succinate sustained-release tablets

MORE PRODUCTS TO

BE ADDED INTO THE PIPELINE

22

Non-Pharma Product Pipeline

Indications Supplier Products Name 2013 2014 2015 2016 2017

Medical Devices

Orthopedic Medtronic/Kanghui Spine Balloon(PKP)

Dental HC-BIOS Dental Implant

Ophthalmology Suzhou Micro Clear

Scanning Laser Ophthalmoscope

Fluorescence Scanning Laser Ophthalmoscope

Handheld-Fundus Camera

IVD reagents

RNA Diagnosis RenduBiotechnology HIV/HBV/HCV

MORE PRODUCTS

TO BE ADDED

INTO THE PIPELINE

3. Leverage Strengths of Strategic Partners

Taiwanese partnership

Strategic investments in TW pharma and med device companies

Source high-market-potential TW products

MNC partnership In-license mature, registered, high-growth drugs from MNCs

Enter new therapeutic areas

Local joint ventures Product co-development to boost profitability

Local M&A Expand geographic reach

Increase product offerings

23

24

Value Creation Via Strategic Alliances

Colandmarketing

FormulationAPI

We aim to integrate API, Formulation & Marketing

For Example: Coland has formed a strategic alliance with ScinoPharm to co-develop oncologyproducts for the China market

ScinoPharm will exclusively provide APIs

Coland & ScinoPharm will jointly engage a formulation partner

Coland will manage the CFDA filing process and marketing

25

Value Creation – Coland Style

Executive Summary

Strategy for Future Growth

Appendix

Outstanding Performance

Financial Performance

26

Historical Performance

2006 2007 2008 2009 2010 2011 2012

Net Sales $570 $1,244 $1,671 $1,573 $1,509 $1,503 $1,722 Net Income $75 $246 $390 $459 $369 $314 $303

$0

$200

$400

$600

$800

$1,000

$1,200

$1,400

$1,600

$1,800

$2,000

(NTD mn)

27

Consolidated Income Statement

NTD Million 2013 Q2 2013 Q1 +/-% 2013 1H 2012 1H +/-%

Net Sales 456 100% 457 100% 0% 912 100% 791 100% 15%

Gross Profit 258 57% 243 53% 6% 502 55% 477 60% 5%

Operating Expense 185 41% 158 35% 17% 343 37% 280 35% 22%

Operating Profit 73 16% 86 18% -14% 159 18% 197 25% -19%

Non-Opt income/Exp 77 17% 73 16% 7% 150 16% 45 6% 233%

Profit Before Tax 151 33% 158 34% -5% 309 34% 242 31% 28%

Profit After Tax 120 26% 135 29% -11% 254 28% 179 23% 42%

Minority Interest 7 2% 7 2% 0% 15 2% 0 0% 100%

Net Profit 112 25% 127 28% -12% 239 26% 179 23% 34%

Basic EPS (NTD) 1.60 1.82 3.42 2.56

EPS is based on a total of 70 million issued shares.

28

Consolidated Balance Sheet

NTD Million 2013-6-30 2013-3-31 2012-12-31

Cash & Equivalents 920 33% 1,033 39% 930 40%

Accounts Receivable 356 13% 324 12% 365 16%

Inventory 163 6% 85 3% 81 3%

Long Term Investments 688 25% 662 25% 441 19%

Fixed Assets 11 0% 8 0% 9 0%

Intangible Assets 390 14% 389 15% 383 16%

Total Assets 2,798 100% 2,629 100% 2,337 100%

Short term Liabilities 419 15% 166 6% 142 6%

Long term & other liabilities 110 4% 108 4% 143 6%

Shareholders’ Equity 2,269 81% 2,355 90% 2,053 88%

Key Indices

Days Sales Outstanding 68 69 68

Inventory Turnover Days 57 36 39

29

1H13 Sales Breakdown

1H 13

Others,4%

1H 12

Notes: 1. Sales from Heilongjiang Tong-ze accounted for 21% of total 1H 13 sales.2. Others : Anti-infective, Immunomodulatory, Neuro system, Biological, Digestive system, etc.

Cardiovascular8%

Hepatits,83%

Medical Device,13%

Hepatits,68%

Respiratory,2%

MedicalDevice,11%

Others,11%Respiratory,1%

Dividends paid in 2011 and 2012

30

Source: TWSENote 1：Stock price based on closing price on 20 Jun 2012, the day before Ex-div dateNote 2：Stock price based on closing price on 10 July 2013, the day before Ex-div date

( NTD Million ) 2011 2012

Net income 314 303

Cash dividend 280 224

Dividend p/s (NT$) 4.0 3.2

Cash yield (%) 5.9*1 4.6*2

Payout ratio (%) 89% 74%

31

1H13 Milestones

Invested in ShanghaiRenduBiotechnology

Enter the China market for high-vitro diagnostic reagents

Invested inTaiwan HC-BIOS

To develop dental implant products for the China market

Invested in Suzhou Microclear

Enter the eye fundus photography laser scanning device market

Strategic alliance with Taiwan ScinoPharm

Co-develop oncologyproducts for the China market

Cooperation with KanghuiMedical

Obtain exclusive agency rights in Shanghai for spine balloon products

RenduHC-BIOS MicroclearScinoPharm Kanghui

Rx drugs Medical devices IVD reagents

32

• We aim to become the leading China-focused company specialized in the commercialization of healthcare products in China.

• We hope to sustain stable earnings growth. • We intend to maintain a consistently higher-

than-industry- average cash dividend payout to shareholders.

• We also pledge that our primary focus will be the maximization of returns to our shareholders via the profitable long-term growth of our core business.

Our Commitment to Shareholders

33

Value Creation – Coland Style

Executive Summary

Strategy for Future Growth

Outstanding Performance

Financial Performance

Appendix

Coland’s Existing Collaborations

34GSK

Medtronic

Anhui Beike

Hangzhou Jiuyuan

Zhejiang Xianju Pharma

Taiwan Lotus Pharma

Taiwan Nanguang Pharma

Pharma Dax

Taiwan Biotech Company

TIPR

pfizer

ScinoPharm Taiwan Ltd

HC Bio-S

Rendu Biotechnology

Micro Clear

Coland: the Go-To Partner for TW Pharma

Coland: The ideal platform for quality Taiwanese drugs and medical devices seeking entry into the vast China market

35

Partner Drug Name Drug Name Origin Brand Name Disease Type Mkt Launch

Taiwan Biotech Co 吸入用複方異丙托溴銨溶液Compound ipratropium

bromide BI可必特

Combivent COPD 2014

Taiwan NanguangPharma

鹽酸伊立替康注射液 Irinotecan Injection Pfizer開普拓Campto Cancer 2014

Lotus Pharma 替莫唑胺膠囊 Temozolomide capsule Merck泰道

Temodal Cancer 2017

PharmaDax 琥珀酸美托洛爾緩釋片Metoprolol succinate

sustained-release Tablets AstraZeneca倍他樂克

BetalocZOK(Toprol-XL)

Cardio 2017

Scinopharm 注射用硼替佐米 Bortezomib Takeda萬珂

Velcade Cancer 2017

36

An Introduction of HC-BIOS

Founded: Oct, 2007. 2011 Ti-One ® 101 Taiwan listed

Obtained CE 0123 and ISO 13485 Certifications in 2011 & U.S.A. FDA certification in 2012

Develops and manufactures dental implant systems

Dental implants

Orthopedic (trauma)

Innovative Surface Treatment- SLAffinity®

Helps the implant to absorb proteins and growth factors in the blood

Accelerates the initial osseointegration and shortens the alveolar bone healing process

Price positioning is between first and second-tier international brands

America, Europe and Korea

The functional and aesthetic demands of patients are increasing as the general population ages and life expectancy increases

The global dental implant market size was US$3B as of 2010. China represented less than 1% of this market and demand in China is growing at more than 30% annually

SLAffinity SLA

HC-BIOS

Products

Advantage

Competitors

Future growth

37

An Introduction of Microclear

Suzhou Microclear

Founded: June, 2011. Based in Suzhou Industrial Park.

Founder Dr. Li was a researcher at the Houston Medical Center for Clinical Ophthalmology

Microclear’s scopes integrate optical, mechanical, electronic, and image processing technology

Products Scanning Laser Ophthalmoscope (2014.10)

Fluorescence Scanning Laser Ophthalmoscope (2014.11)

Handheld-fundus Camera (2015.06)

Advantage

One shot vs. Video

White light vs. IR light

Pupil size: 2.5mm vs. 1.5mm

Visual field: 30°~45° vs. 30°~60°

Competitors Microclear is the only China-based company to develop this technology

Germany (HEIDELBERG), England (OPTOS) and Holland (IOPTICS)

Future growth Demand from tier II hospitals, fundus screening, medical centers and other market segments

Based on current market trends, Scanning Laser Ophthalmoscopes will replace Fundus Cameras

The Chinese ophthalmic market is expected to reach 4 billion RMB

38

An Introduction of Rendu Biotechnology

Rendu Biotech Founded by a Chinese-American scientist in June, 2007

Based in Zhangjiang High Technology Park, Shanghai

Manufacture and sales of SAT (Simultaneous Amplification and Testing) equipment & reagents

Products

Full automatic RNA extractor

CT/NG/UU/MG Detection

TB/EV71/CA16/EV Detection

HIV/HBV/HCV Virus Diagnosis

Advantage

Fully automatic , improves process standardization, and reduces operator workload

Higher sensitivity and specificity for pathogen testing

Less contamination - RNA degrades easily

Convenient testing method (urine test), rapid delivery of results (2hrs vs. 14 days)

Competitors Rendu is the only China-based company that has RNA detection products and pipelines

Gen-Probe (TMA), Biomerieux (NASBA) have not entered the China market

China-based competitors: Molecular, Immuno-assay, Sansure

Future growth Global IVD market is US$35B, or 12% of total lab tests, and RNA detection is a leading method

China IVD market is only 1-2% total lab tests, and RNA detection is just beginning

RNA Diagnosis market growth in China is 25-30% annually, higher than general IVD market

China Pharmaceutical Market Forecasts

• China was the third largest pharma market in the world in 2011, according to IMS.• China’s health expenditure reached 5.4% of GDP in 2010, much lower than the

average 10% for developed countries and 16% for US.• China’s health care expenditures are projected to increase at a 20% CAGR between

2011 and 2016. China is projected to become the second largest Pharma market in the world in 2020, according to market research.

39

1 USA

2 Japan

3 China

4 Germany

5 France

6 Italy

7 Spain

8 Brazil

9 UK

10 Canada

1 USA

2 Japan

3 France

4 Germany

5 China

6 Italy

7 Spain

8 UK

9 Brazil

10 Canada

1 USA

2 Japan

3 Germany

4 France

5 UK

6 Italy

7 China

8 Brazil

9 Canada

10 Spain

1 USA

2 Japan

3 Germany

4 France

5 UK

6 Italy

7 China

8 Brazil

9 Canada

10 Spain

Source：IMS, PRC government publications, estimates from independent research firms.

Year 2005 Year 2009 Year 2011Year 2000

Targeting High Growth Market Segments

40

Source: IMS May 2013

Therapeutic Subcategory

China market(Million RMB)

2011/12-2012/11

CAGR (%) 2007-2012

Growth rate(%) 2012 vs.2011

Anti-infectives 83,049 10 0.4

Metabolism 58,080 25 24.0

Cardiovascular 57,176 25 27.4

Oncology 43,296 24 26.1

Respiratory 12,569 29 29.5

Targeted market segments have a

combined market size of

RM196 Bn with a projected 20%+ CAGR from 2007

to 2012

41

Investing in Medical Devices and IVD

• In 2012, the China IVD Reagent market reached US$1.7B

• It is projected to reach US$2.7B in 2015, with a CAGR of 20%+ between 2007-2015

950 1078 1211 1356 1534 1724 1933 2178 2450 2754268332

412492

606733

896

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

12.9%

20.8%

14.3%

Natural Growth Policy Driven Patient Driven

Market Size – Medical Equipment (in Hundred Million RMB)

501 794

1,259

1,712

2,714

-

500

1,000

1,500

2,000

2,500

3,000

2004 2007 2010 2012 2015

Market Size - IVD Reagent (in Million USD)

Source: Deutsche Bank

Source: Kalorama

20%+

• Prior to 2008: Medical device replacement as result of “wear and tear”

• 2009 to 2011: State-owned hospitals make collective purchases in the period of Medical System Reform

• 2012 to now: Increases in medical insurance coverage stimulate demand

42

Medical Devices Market

0%20%40%60%80%

100%41% 40% 41% 41% 42% 42% 42% 42%

Global pharmaceutical and medical devices market

Global pharmaceutical market

Global medical devices market

0%20%40%60%80%

100% 10% 10% 11% 11% 12% 13% 14% 14%

China pharmaceutical and medical devices market

China pharmaceutical market

China medical devices market

19% 20% 19% 20%23% 23% 23% 23%

25% 24%

17%14% 14%

17%14% 15%

17% 18% 17%19%

0

0.05

0.1

0.15

0.2

0.25

0.3

0200400600800

100012001400

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

China medical device market(in Hundred Million RMB)

medical devices market size

medical devices market growth rate

pharmaceutical market growth rate

• Med device sales as % of total pharma + med devices mkt: China(15%) vs. Global(40%)

• Average expenditure on medical products per capita: China: US$ 13/per person vs. US: US$ 329/per person

• Demand driven by medical insurance increase and expansion

Source: Chinese Medical Device Industry Association

43

Dental Implant Market

Other Area,10%

China, Less than1%

Global Dental Implants Market255

192168

145133107

8763 57 54 44 39 35 25 18 17 7 1

Penetration rate of dental implants in 2008

The number of dental implants/ten thousand people

Source: Medical Technology, Merrill Lynch, 2007/Global Dental Implants Market, M&M, July2010

Europe,47%North America,27%

Asia Pacific,16%

Source: Straumann 2010

• Both functional and aesthetic demands of patients are increasing.

• The general population is aging and life expectancy is increasing. Tooth loss is a function of age.

• There is significant potential demand emerging in China. 0

50010001500200025003000350040004500

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

773 886 1011 1147 1230 1378 1503 1631 1751 1867 1980445 560 693850 920 1021 1115 1208 1301 1386 1468

290347

413485 545

590630

679740

812897

Dental Implant Market Size(in Million USD)

Europe USA Asia Pacific

Source: Biomet/3i

COLAND GROUPTEL：+86-21-5137-1880FAX：+86-21-5137-1882/51371883ADD：1st Floor, No. 866, Halei Rd, Zhangjiang Hightech Park, Shanghai, ChinaTaipei OfficeTEL：+886-2-2546-9288FAX：+886-2-2546-6599 ADD：Rm. D, 10F., No.170, Dunhua N. Rd., Songshan Dist., Taipei City 105, TaiwanWEB：www.colandpharma.com

Thank you!